At a glance
ClinicalIndex Comparison Record- ✓Age 18-75 years old
- ✓ECOG performance status 0-1
- ✓Histologically or cytologically confirmed head squamous cell carcinoma from oral cavity, oropharynx, hypopharynx or larynx
- ✓Recurrent and/or metastatic HNSCC without indications for local radical treatment
- ✕Suitable for local treatment and willing to receive local treatment
- ✕Prior systemic chemotherapy (except multimodal therapy completed >6 months before first dose)
- ✕Disease progression within 6 months of completing multimodal therapy for locally advanced HNSCC
- ✕Prior anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, anti-CTLA-4 antibodies or other T cell co-stimulation or immune checkpoint pathway therapy
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NCT04857164Phase 2RecruitingUpdate OverdueUpdated 17mo ago · Completion was 34mo agoA Prospective Study of Pembrolizumab Combined with Chemotherapy (cisplatin or Carboplatin + Albumin-bound Paclitaxel) in First-line Therapy for Patients with Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck
In Brief
A Phase 2 clinical trial evaluating Pembrolizumab combined with Chemotherapy for Head and Neck Squamous Cell Carcinoma. Currently recruiting, targeting 150 participants across 1 site.
Signals
Detailed Summary
This trial is main evaluate the efficacy and safety of pembrolizumab combined with chemotherapy in the first-line treatment of Chinese patients with recurrent or metastatic head and neck squamous cell carcinoma
Study Details
Timeline
Interventions
Pembrolizumab (formerly lambrolizumab, brand name Keytruda) is a humanized antibody used in cancer Chemotherapy regimen is selected by the investigator immunotherapy. This includes to treat melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, and stomach cancer.